The Administration Core is the central core of the Mayo Clinic SPORE in Ovarian Cancer. It will provide organizational support for the leadership of the SPORE, facilitate communication among the component activities of the SPORE, and provide an organizational portal for collaborations outside the SPORE. Specifically, the Administration Core will: 1) provide leadership, organizational support, and financial management for SPORE investigators;2) oversee formal procedures for systematic scientific review of SPORE research projects;3) oversee and coordinate the efforts of all cores to ensure that the research projects are supported effectively;4) monitor'accrual, including minority accrual, to all SPORE clinical trials and biospecimen collections;5) provide administrative support to the Developmental Research Program and Career Developmental Program;6) assure ongoing integration and participation of the Ovarian SPORE in the activities of the Mayo Clinic Cancer Center;7) facilitate activities of the Ovarian SPORE advocates; 8) serve as the administrative liaison between the Mayo Clinic SPORE and the NCI SPORE Program, other Mayo SPOREs, and external collaborators;and 9) communicate SPORE-related research developments among the Mayo Clinic SPORE investigators, to the scientific community at large, and to the public. Dr. Hartmann will direct the Administration Core, in close consultation with the SPORE Co-PI/Administration Core Co-Director, and Executive Committee, to maximize the effectiveness of the Ovarian SPORE effort and its clinical-translational impact.
The Administration Core provides the organizational infrastructure necessary to perform the work proposed in this SPORE application.
|Lengyel, Ernst; Litchfield, Lacey M; Mitra, Anirban K et al. (2015) Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. Am J Obstet Gynecol 212:479.e1-479.e10|
|Earp, Madalene A; Kelemen, Linda E; Magliocco, Anthony M et al. (2014) Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Hum Genet 133:481-97|
|Liu, Yu-Ping; Wang, Jiahu; Avanzato, Victoria A et al. (2014) Oncolytic vaccinia virotherapy for endometrial cancer. Gynecol Oncol 132:722-9|
|Fridley, Brooke L; Armasu, Sebastian M; Cicek, Mine S et al. (2014) Methylation of leukocyte DNA and ovarian cancer: relationships with disease status and outcome. BMC Med Genomics 7:21|
|Trabert, Britton; Ness, Roberta B; Lo-Ciganic, Wei-Hsuan et al. (2014) Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst 106:djt431|
|Parker, Peter J; Justilien, Verline; Riou, Philippe et al. (2014) Atypical protein kinase Cýý as a human oncogene and therapeutic target. Biochem Pharmacol 88:1-11|
|Scott, Clare L; Mackay, Helen J; Haluska Jr, Paul (2014) Patient-derived xenograft models in gynecologic malignancies. Am Soc Clin Oncol Educ Book :e258-66|
|Charbonneau, Bridget; Moysich, Kirsten B; Kalli, Kimberly R et al. (2014) Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome. Cancer Immunol Res 2:332-40|
|Brewer, LaPrincess C; Hayes, Sharonne N; Parker, Monica W et al. (2014) African American women's perceptions and attitudes regarding participation in medical research: the Mayo Clinic/The Links, Incorporated partnership. J Womens Health (Larchmt) 23:681-7|
|King, Helen; Aleksic, Tamara; Haluska, Paul et al. (2014) Can we unlock the potential of IGF-1R inhibition in cancer therapy? Cancer Treat Rev 40:1096-105|
Showing the most recent 10 out of 86 publications